Expression levels and clinical significance of YKL-40 in serum and peritoneal fluid of patients with endometriosis
article
OA: closed
CC0
AI-generated summary
Serum and peritoneal fluid levels of YKL-40 were significantly higher in endometriosis patients compared to controls and correlated positively with CA125.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
AI-generated deep summary
This study measured serum and peritoneal fluid YKL-40 and CA125 in 50 confirmed endometriosis patients and compared them with 40 controls with benign uterine tumors, using ELISA for YKL-40 and electrochemiluminescence for CA125, followed by statistical comparisons and Spearman correlation. YKL-40 and CA125 levels were higher in the endometriosis group than in controls (P<0.05), and within endometriosis, patients with stage III–IV had higher levels than those with stage I–II (P<0.05). The paper also found a significant positive correlation between serum and peritoneal fluid YKL-40 and CA125 in endometriosis patients (r=0.504 and 0.401; P<0.01). A limitation explicitly noted from the provided text is the small sample size and the use of benign uterine tumor controls rather than another pelvic-pain comparator group. This paper is centrally about endometriosis—specifically, assessing serum and peritoneal fluid YKL-40 (and CA125) as diagnostic and stage-indicative biomarkers.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Objective
To investigate the expression levels of YKL-40 and CA125 in the serum and peritoneal fluid of patients with endometriosis (EMS), and discuss the relationship between YKL-40, and CA125.
Methods
From March 2012 to March 2014, a total of 50 cases with EMS were included into this study (EMS group). At the same time, another 40 cases with benign uterus tumor were included into control group. There were no significant differences between two groups in the aspects of age, body mass index, the constituent ratio of algomenorrhea, the constituent ratio of infertility, and duration of infertility (P>0.05). The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Xuzhou Central Hospital, Affiliated Reproductive Medical Central of Southeast University. Informed consent was obtained from each patient. Serum and peritoneal fluid levels of YKL-40 in both two groups were detected by enzyme-linked immunosorbent assay (ELISA), and serum and peritoneal fluid levels of CA125 were detected by electrochemiluminescence method. The relationship between CA125, YKL-40 and EMS were analyzed by Spearman correlation analysis.
Results
①The serum and peritoneal fluid levels of CA125 and YKL-40 in EMS group were both significantly higher than those of control group, which with significant differences (P<0.05). ②The serum and peritoneal fluid levels of CA125 and YKL-40 in stage Ⅲ-Ⅳ of EMS group were significantly higher than those of stage Ⅰ-Ⅱ, which with significant differences (P<0.05). The serum levels of YKL-40 in stage Ⅰ-Ⅱ, stage Ⅲ-Ⅳwere significantly higher than those of control group, and the peritoneal fluid levels of YKL-40, CA125 in stage Ⅰ-Ⅱ, stage Ⅲ-Ⅳwere significantly higher than those of control group, respectively, which both with significant differences (P<0.05). ③Serum and peritoneal fluid levels of YKL-40 showed positive correlation with CA125 (r=0.504, 0.401; P<0.01) by Spearman correlation analysis (P<0.05).
Conclusions
The serum and peritoneal fluid levels of YKL-40 might be an useful diagnosing and prompting clinical staging biomarker of EMS.
Key words:
Endometriosis; YKL-40; Clinical staging
Full text
8,072 characters
· extracted from
oa-doi-fallback
· 4 sections
· click to expand
Objective
To investigate the expression levels of YKL-40 and CA125 in the serum and peritoneal fluid of patients with endometriosis (EMS), and discuss the relationship between YKL-40, and CA125.
Methods
From March 2012 to March 2014, a total of 50 cases with EMS were included into this study (EMS group). At the same time, another 40 cases with benign uterus tumor were included into control group. There were no significant differences between two groups in the aspects of age, body mass index, the constituent ratio of algomenorrhea, the constituent ratio of infertility, and duration of infertility (P>0.05). The study protocol was approved by the Ethical Review Board of Investigation in Human Being of Xuzhou Central Hospital, Affiliated Reproductive Medical Central of Southeast University. Informed consent was obtained from each patient. Serum and peritoneal fluid levels of YKL-40 in both two groups were detected by enzyme-linked immunosorbent assay (ELISA), and serum and peritoneal fluid levels of CA125 were detected by electrochemiluminescence method. The relationship between CA125, YKL-40 and EMS were analyzed by Spearman correlation analysis.
Results
①The serum and peritoneal fluid levels of CA125 and YKL-40 in EMS group were both significantly higher than those of control group, which with significant differences (P<0.05). ②The serum and peritoneal fluid levels of CA125 and YKL-40 in stage Ⅲ-Ⅳ of EMS group were significantly higher than those of stage Ⅰ-Ⅱ, which with significant differences (P<0.05). The serum levels of YKL-40 in stage Ⅰ-Ⅱ, stage Ⅲ-Ⅳwere significantly higher than those of control group, and the peritoneal fluid levels of YKL-40, CA125 in stage Ⅰ-Ⅱ, stage Ⅲ-Ⅳwere significantly higher than those of control group, respectively, which both with significant differences (P<0.05). ③Serum and peritoneal fluid levels of YKL-40 showed positive correlation with CA125 (r=0.504, 0.401; P<0.01) by Spearman correlation analysis (P<0.05).
Conclusions
The serum and peritoneal fluid levels of YKL-40 might be an useful diagnosing and prompting clinical staging biomarker of EMS.
| [1] |
Heidemann LN, Hartwell D, Heidemann CH, et al.The relation between endometriosis and ovarian cancer - a review [J]. Acta Obstet Gynecol Scand, 2014, 93(1): 20–31.
|
| [2] |
Esmaeilzadeh S, Mirabi P, Basirat Z, et al. Association between endometriosis and hyperprolactinemia in infertile women [J]. Iran J Reprod Med, 2015, 13(3): 155–160.
|
| [3] |
马华姝，乔宗旭，赵贵芬，等.二甲双胍对子宫内膜异位症在位内膜细胞增殖与凋亡的影响[J/CD]. 中华妇幼临床医学杂志：电子版，2014，10(5): 652–657.
|
| [4] |
朱丽莎，刘玲，邓燕杰. 卵巢透明细胞癌合并卵巢子宫内膜异位症的临床病理学分析[J/CD]. 中华妇幼临床医学杂志：电子版，2015, 11(1): 64–68.
|
| [5] |
Johansen JS, Cintin C, Jørgensen M, et al. Serum YKL-40: a new potential marker of prognosis and location of metastases of patients with recurrent breast cancer [J]. Eur J Cancer, 1995, 31A(9)：1437–1442.
|
| [6] |
曾俐琴，王颀，孙小丽，等. 乳腺癌相关治疗导致妇科并发症的研究进展[J/CD]. 中华妇幼临床医学杂：电子版，2012, 8(6): 674–678.
|
| [7] |
Gronlund B1, Høgdall EV, Christensen IJ, et al. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125)[J]. Int J Biol Markers, 2006, 21(3)：141–148.
|
| [8] |
马志华，吕东昊. 子宫内膜异位症相关卵巢癌的临床诊治进展[J/CD]. 中华妇幼临床医学杂志：电子版，2013, 9(6): 828–832.
|
| [9] |
Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL-40 as a marker for cervical adenocarcinoma[J]. Ann Oncol, 2009, 20(1): 71–77.
|
| [10] |
Haas D, Wurm P, Shamiyeh A, et al. Efficacy of the revised Enzian classification: a retrospective analysis. Does the revised Enzian classification solve the problem of duplicate classification in rASRM and Enzian？[J]. Arch Gynecol Obstet, 2013, 287(5): 941–945.
|
| [11] |
Veillat V, Sengers V, Metz CN, et al. Macrophage migration inhibitory factor is involved in a positive feedback loop increasing aromatase expression in endometriosis [J]. Am J Pathol, 2012, 181(3): 917–927.
|
| [12] |
Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer [J]. Dan Med Bull, 2006, 53(2): 172–209.
|
| [13] |
Tuten A, Kucur M, Imamoglu M, et al. Serum YKL-40 levels are altered in endometriosis[J]. Gynecol Endocrinol, 2014, 30(5): 381–384.
|
| [14] |
Zou L, He X, Zhang JW. The efficacy of YKL-40 and CA125 as biomarkers for epithelial ovarian cancer[J]. Braz J Med Biol Res, 2010, 43(12)：1232–1238.
|
| [15] |
Stawerski P, Wágrowska-Danilewicz M, Stasikowska-Kanicka O, et al. Increased tissue immunoexpression of YKL-40 protein in high grade serous ovarian cancers[J]. Pathol Res Pract, 2011, 207(9)：573–576.
|
| [16] |
Thöm I, Andritzky B, Schuch G, et al. Elevated pretreatment serum concentration of YKL-40. An independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer[J]. Cancer, 2010, 116(17): 4114–4121.
|
| [17] |
Kim PJ, Hong DG, Park JY, et al. Immunohistochemical expression of YKL-40 in peritoneal endometriosis[J]. Gynecol Endocrinol, 2010, 26(1)：58–62.
|
| [18] |
赖繁，蔡一玲，赵虎. 子宫内膜异位症患者血清及组织OPN、CA125、HMGB1、VEGF及其受体的变化研究[J]. 成都医学院学报，2014, 9(3): 339–341.
|
| [19] |
杨岚，郭友逢，王丽峰，等. CA125，CA19-9在子宫内膜癌组织学和血清学中表达水平的差异性及相关性研究[J/CD]．中华妇幼临床医学杂志：电子版，2013，9(2): 189–192.
|
| [20] |
成萍，纪燕琴．子宫内膜异位症发病机制的研究进展[J/CD]．中华妇幼临床医学杂志：电子版，2015，11(1): 121–123.
|
| [1] | 朱成美, 赵巧梅, 邓学东. 经阴道超声联合生理盐水灌注直肠子宫陷凹对腹膜型子宫内膜异位症的诊断价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(01): 32-36. |
| [2] | 乔林. 子宫内膜异位症鉴别诊断病例分享[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 248-. |
| [3] | 魏丽坤, 张旭红, 罗营, 薛凤霞, 王颖梅, 宋学茹, 田丽娜, 张艳芳, 王艳霞, 田文艳. 卵巢子宫内膜异位囊肿发生恶变并发盆腔脓肿1例并文献复习[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 696-702. |
| [4] | 罗丹, 孔为民, 陈姝宁, 赵小玲, 谢云凯. 子宫内膜异位症患者在位及异位内膜上皮细胞-间充质转化相关生物标志物的变化[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 530-539. |
| [5] | 杨泽成, 史常赛, 陈佳乐, 李金龙. 腹壁子宫内膜异位症相关性透明细胞癌一例及文献回顾[J/OL]. 中华疝和腹壁外科杂志(电子版), 2022, 16(05): 595-599. |
| [6] | 张蕾, 彭超, 周应芳. 直肠阴道隔子宫内膜异位症腹腔镜手术技巧[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 257-261. |
| [7] | 胡启明, 鄢潇, 尤志学, 黄骁昊. 经瘢痕处单孔腹腔镜下切除多病灶腹壁子宫内膜异位症[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(05): 314-317. |
| [8] | 芦煜, 李振宇, 吴承东, 周仲伍. 肛周子宫内膜异位症一例报告[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(05): 431-434. |
| [9] | 杨菲, 刘腾飞, 赵志军, 李睿聪, 张颉, 刘妍, 赵珍. 血清维生素水平与分化型甲状腺癌的关联性研究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 633-640. |
| [10] | 陈娟, 邓静敏. 胸部子宫内膜异位综合征的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(01): 96-100. |
| [11] | 王丁然, 迟洪滨. 自身免疫甲状腺炎对子宫内膜异位症患者胚胎移植结局的影响[J/OL]. 中华临床医师杂志(电子版), 2023, 17(06): 682-688. |
| [12] | 王宁, 吴慢莉, 杨东霞. 代谢组学生物标志物：子宫内膜异位症诊疗的新靶点[J/OL]. 中华临床医师杂志(电子版), 2022, 16(12): 1280-1283. |
| [13] | 兰素伟, 王春辉, 常丽凤, 王杏茶, 翟明晶, 李阳. 血清miRNA-10b和miRNA-34a在子宫内膜异位症患者中的表达及与术后复发关系研究[J/OL]. 中华临床医师杂志(电子版), 2022, 16(08): 759-763. |
| [14] | 汪泉, 周英妹, 何颖. p27、cyclin-E在子宫内膜异位症中的表达及其临床意义[J/OL]. 中华临床医师杂志(电子版), 2022, 16(06): 546-552. |
| [15] | 洪凡, 陈敦金, 傅洋, 梁新月, 吴毅, 王晓怡. 体外受精-胚胎移植妊娠合并前置胎盘临床研究[J/OL]. 中华产科急救电子杂志, 2024, 13(03): 176-182. |
| 阅读次数 | |||||
|
全文 |
|
||||
|
摘要 |
|
||||
版权所有 中华医学会 中华医学电子音像出版社有限责任公司 京ICP备14006079号-1 网络出版服务许可证：(署)网出证(京)字第075号
AI
小
编
AI小编
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Ask this paper
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK